Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381841 | 0.94 | EGFR (0.32) | EGFR | |
| SCHEMBL4379549 | 0.89 | EGFR (0.33) | ALOX5EGFR | |
| SCHEMBL4388969 | 0.88 | EGFR (0.34) | EGFR | |
| SCHEMBL4386514 | 0.85 | EGFR (0.37) | EGFR | |
| SCHEMBL4378212 | 0.83 | EGFR (0.38) | EGFR | |
| SCHEMBL4384192 | 0.83 | EGFR (0.34) | EGFR | |
| SCHEMBL4384363 | 0.82 | USP7 (0.32) | — | |
| SCHEMBL4379005 | 0.82 | MEN1 (0.34) | EGFR | |
| SCHEMBL4381681 | 0.82 | EGFR (0.36) | EGFR | |
| SCHEMBL4379642 | 0.81 | EGFR (0.37) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | ALOX5 4819/4885EGFR 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.